American Journal of Cardiovascular Drugs

 
 

  • Non-inferiority Trial Design in Drug Development Review the role of noninferiority trials in the development of new cardiovascular treatments. What are the key issues involved in the design and conduction of this type of drug trial?
  • Obesity Paradox in AF: Relationship With OACs What might account for the apparent paradox that while obesity and AF are clearly related, overweight and obese patients with AF may have a better prognosis than healthy-weight patients?
  • Key Features of the 2018 Guidelines on Cholesterol Management This article summarizes the main clinical recommendations as presented in the 2018 Guideline on the Management of Blood Cholesterol, a collaborative effort of key cardiology societies.
  • Review of DOACs and Guide for Effective Drug Utilization This article reviews the pharmacology, indications, and contraindications of currently available direct oral anticoagulants, with a focus on selecting the appropriate DOACs in clinical practice.
  • Adenosine and the Cardiovascular System A new review explores the impacts of adenosine on the heart and cardiovascular system and discusses its potential as a clinical treatment.
  • Rivaroxaban With/Without Aspirin for Secondary CVD Prevention Is there a role for very low-dose rivaroxaban in patients with stable atherosclerotic disease?
  • Cardiovascular Protection With Anti-Hyperglycemic Agents Anti-hyperglycemic drugs are commonly used in the treatment of diabetes. Could certain agents provide cardiovascular benefits as well?
  • Emerging Drugs for Residual CV Risk in Statin-Treated Adults Learn about the many novel therapeutics recently approved or under development which target LDL-C and/or triglycerides via different mechanisms than do statins.
  • Angiotensin II for Treatment of Distributive Shock A new formulation of angiotensin II has received rapid FDA approval for treatment of distributive shock, which is often refractory to other treatment and has a high mortality rate.
  • Clinical Use of Digitalis: A State of the Art Review Digitalis has been used for medicinal purposes for hundreds of years--and continues to have value in the cardiovascular armamentarium. Review its history and current clinical role in this paper.
  • Atrial Fibrillation in Patients With Heart Failure Atrial fibrillation frequently coexists with heart failure and may result in increased adverse outcomes. Review therapeutic considerations and best approaches to treatment in this article.
  • Combination Therapy for Pulmonary Arterial Hypertension This article reviews practical recommendations for the use of combination therapy for the treatment of pulmonary arterial hypertension, including monitoring and management of side effects.
  • CoQ10 Supplementation and Statin-Associated Muscle Symptoms Deficiency of CoQ10, or ubiquinone, has been proposed as a mechanism underlying statin-associated muscle symptoms. This review examines the current evidence.
  • Benefit-Risk Assessment of Crataegus Extract WS 1442 Crataegus--commonly known as hawthorn--has long been used in the treatment of heart failure. Might it be a safe and effective adjunct in current clinical practice?
  • Nuclear Cardiology: Correct Use of Protocols and Tracers How can we improve the safety of nuclear cardiology studies without compromising results? This review examines different radiopharmaceuticals and study protocols and their impact on safety.
  • Management of Heart Failure With Preserved Ejection Fraction This article presents a summary of traditional as well as emerging pharmacotherapies for heart failure with preserved ejection fraction, the most common form of HF in the elderly.
  • Iron Therapy in Patients With HF and Iron Deficiency Iron deficiency is common in heart failure patients, but supplementation needs to be addressed differently than in healthy patients. What are the options?
  • Optimizing the Use of Cangrelor in the Real World Cangrelor is a potent P2Y12 receptor antagonist for I.V. administration, providing a rapid onset and maximal platelet inhibition. What do you need to know to use it safely and effectively?
  • Targeting Cellular Stress to Prevent Cardiovascular Disease This paper explores the role of oxidative stress, inflammation and other cellular stresses in cardiovascular disease. Might reducing cellular stress provide a therapeutic target for CVD prevention?
  • Intracoronary Bivalirudin in STEMI Patients Treated With PCI This report describes a novel off-label protocol for bivalirudin administration in patients with STEMI undergoing PCI. What advantages does it offer over the standard intravenous route?